Cathie Wood's position in CRISPR Therapeutics AG is currently worth $636 Million. That's 4.64% of their equity portfolio (3rd largest holding). The investor owns 12.64% of the outstanding CRISPR Therapeutics AG stock. The first CRISPR Therapeutics AG trade was made in Q2 2017. Since then Cathie Wood bought shares fourteen more times and sold shares on four occasions. The investor's estimated purchase price is $709 Million, resulting in a loss of 10%.
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be vol...Benzinga, about 2 months ago
Source: rhendrikdwenz via Shutterstock So far, 2022 has been a rocky year for Cathie Wood’s exchange-traded funds (ETFs). Her flagship fund, the ARK Innovati...InvestorPlace, 3 months ago